Sakamaki Yoshie, Ozdemir John, Perez Alda Diaz, Heidrick Zachary, Watson Olivia, Tsuji Miu, Salmon Chirstopher, Batta-Mpouma Joseph, Azzun Anthony, Lomonte Valerie, Du Yuchun, Stenken Julie, Woo-Kim Jin, Beyzavi M Hassan
Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Department of Biological and Agricultural Engineering, Institute for Nanoscience and Engineering, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Adv Ther (Weinh). 2020 Aug;3(8). doi: 10.1002/adtp.202000029. Epub 2020 Jun 8.
Herein, we report a nano-MOF conjugated to maltotriose as a new DDS. MA-PCN-224-0.1Mn/0.9Zn showed its ability to target cancer and TAM. This novel MOF is an effective PDT agent and shows little dark toxicity, MA-PCN-224-0.1Mn/0.9Zn uptakes selectively into cancer cells. A well-suited size control methodology was used so that the nano-scaled MOFs may take advantage of the EPR effect. This development of a nano-scale MOF for PDT that is conjugated to a cancer targeting ligand represents a meaningful development for the use of MOFs as drug delivery systems.
在此，我们报道了一种与麦芽三糖共轭的纳米金属有机框架作为一种新型药物递送系统。MA-PCN-224-0.1Mn/0.9Zn显示出靶向癌症和肿瘤相关巨噬细胞的能力。这种新型金属有机框架是一种有效的光动力治疗剂，且几乎没有暗毒性，MA-PCN-224-0.1Mn/0.9Zn能选择性地摄取到癌细胞中。使用了一种合适的尺寸控制方法，以便纳米级金属有机框架可以利用增强渗透和滞留效应。这种与癌症靶向配体共轭的用于光动力治疗的纳米级金属有机框架的开发，代表了将金属有机框架用作药物递送系统的一项有意义的进展。
